JP2018529745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529745A5 JP2018529745A5 JP2018517532A JP2018517532A JP2018529745A5 JP 2018529745 A5 JP2018529745 A5 JP 2018529745A5 JP 2018517532 A JP2018517532 A JP 2018517532A JP 2018517532 A JP2018517532 A JP 2018517532A JP 2018529745 A5 JP2018529745 A5 JP 2018529745A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- heterocycloalkyl
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 158
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 67
- 125000001424 substituent group Chemical group 0.000 claims 48
- 229910052739 hydrogen Inorganic materials 0.000 claims 41
- 239000001257 hydrogen Substances 0.000 claims 40
- 125000002619 bicyclic group Chemical group 0.000 claims 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 26
- 125000001425 triazolyl group Chemical group 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 22
- 125000004076 pyridyl group Chemical group 0.000 claims 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 125000002098 pyridazinyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- YXDVRIQBOMUBEQ-UHFFFAOYSA-N 2-oxa-8-azaspiro[5.5]undecane Chemical compound C1CCNCC21COCCC2 YXDVRIQBOMUBEQ-UHFFFAOYSA-N 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- 125000003226 pyrazolyl group Chemical group 0.000 claims 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000006413 ring segment Chemical group 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- LGKNCSVHCNCJQG-UHFFFAOYSA-N 1-azaspiro[4.5]decane Chemical compound C1CCNC21CCCCC2 LGKNCSVHCNCJQG-UHFFFAOYSA-N 0.000 claims 6
- SIQBPWRTJNBBER-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-2-benzazepine Chemical compound C1CCNCC2=CC=CC=C21 SIQBPWRTJNBBER-UHFFFAOYSA-N 0.000 claims 6
- FTGUMOQCPJEKOR-UHFFFAOYSA-N 6-oxa-9-azaspiro[4.5]decane Chemical compound C1CCCC21OCCNC2 FTGUMOQCPJEKOR-UHFFFAOYSA-N 0.000 claims 6
- JFNPSSKPSOKMJH-UHFFFAOYSA-N 7-azaspiro[4.5]decane Chemical compound C1CCCC21CNCCC2 JFNPSSKPSOKMJH-UHFFFAOYSA-N 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- HVFHYYCWZWCTMW-UHFFFAOYSA-N 4-azaspiro[2.5]octane Chemical compound C1CC11NCCCC1 HVFHYYCWZWCTMW-UHFFFAOYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000005605 benzo group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 3
- 201000011040 acute kidney failure Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 claims 3
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 208000032376 Lung infection Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- -1 Piridajini Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 claims 2
- HDVHFHONOKCUHQ-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,4-benzoxazepine Chemical compound C1NCCOC2=CC=CC=C21 HDVHFHONOKCUHQ-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010072082 Environmental exposure Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000008518 non respiratory effect Effects 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 0 Cc1cccc(*)c1 Chemical compound Cc1cccc(*)c1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237655P | 2015-10-06 | 2015-10-06 | |
| US62/237,655 | 2015-10-06 | ||
| PCT/IB2016/055996 WO2017060854A1 (en) | 2015-10-06 | 2016-10-06 | Biaryl pyrazoles as nrf2 regulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018529745A JP2018529745A (ja) | 2018-10-11 |
| JP2018529745A5 true JP2018529745A5 (enExample) | 2019-11-21 |
Family
ID=57184570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517532A Pending JP2018529745A (ja) | 2015-10-06 | 2016-10-06 | Ｎｒｆ２レギュレーターとしてのビアリールピラゾール |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10364256B2 (enExample) |
| EP (1) | EP3359532A1 (enExample) |
| JP (1) | JP2018529745A (enExample) |
| WO (1) | WO2017060854A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307739B1 (en) | 2015-06-15 | 2020-10-07 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| KR20180018684A (ko) | 2015-06-15 | 2018-02-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| EP3371167A1 (en) * | 2015-10-06 | 2018-09-12 | GlaxoSmithKline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
| EP3551621A1 (en) * | 2016-12-12 | 2019-10-16 | GlaxoSmithKline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| US11078216B2 (en) | 2016-12-14 | 2021-08-03 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as NRF2 activators |
| JP2020502123A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしてのビスアリール複素環 |
| US11059816B2 (en) | 2016-12-15 | 2021-07-13 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as NRF2 activators |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| US11643407B2 (en) | 2018-05-23 | 2023-05-09 | Glaxosmithkline Intellectual Property Development Limited | Indanes as NRF2 activators |
| US12220525B2 (en) * | 2018-06-27 | 2025-02-11 | Kindeva Drug Deliver L.P. | Tiotropium formulation and inhaler |
| ES2974026T3 (es) | 2018-08-20 | 2024-06-25 | Janssen Pharmaceutica Nv | Inhibidores de la interacción proteína-proteína entre KEAP1-Nrf2 |
| US11518763B2 (en) | 2018-12-05 | 2022-12-06 | Scohia Pharma, Inc. | Macrocyclic compound and use thereof |
| MY209603A (en) * | 2019-02-15 | 2025-07-24 | Glaxosmithkline Ip Dev Ltd | Hydroxypyridoxazepines as nrf2 activators |
| MX2021014680A (es) | 2019-05-31 | 2022-04-06 | Ube Corp | Derivado de benzotriazol. |
| WO2023210741A1 (ja) | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | ベンゾトリアゾール化合物 |
| EP4619399A1 (en) | 2022-11-16 | 2025-09-24 | Basf Se | New substituted tetrahydrobenzoxazepine |
| CN116120252B (zh) * | 2022-12-22 | 2024-10-29 | 浙江工业大学 | 一种雷米普利关键中间体衍生物的制备方法 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
| ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| GB2129691B (en) | 1982-10-08 | 1987-08-05 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| FI88112C (fi) | 1985-07-30 | 1993-04-13 | Glaxo Group Ltd | Anordning foer administrering av laekemedel till patienter |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SK280967B6 (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Inhalačný prístroj |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
| KR100236806B1 (ko) | 1991-12-10 | 2000-01-15 | 시오노 요시히코 | 방향족 설폰아미드계 하이드록삼산 유도체 |
| ATE227567T1 (de) | 1994-05-27 | 2002-11-15 | Merck & Co Inc | Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption |
| GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| WO2002059080A2 (en) | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| WO2002080899A1 (fr) | 2001-03-30 | 2002-10-17 | Eisai Co., Ltd. | Agent de traitement de maladie digestive |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| AU2002341693B2 (en) | 2001-09-21 | 2008-05-29 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| US20040157919A1 (en) | 2002-01-25 | 2004-08-12 | Yong-Qian Wu | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| JPWO2004007464A1 (ja) | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | イミダゾール誘導体 |
| WO2004092140A1 (en) * | 2003-04-03 | 2004-10-28 | Merck & Co., Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
| GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
| CA2555347A1 (en) | 2004-02-16 | 2005-09-01 | Stephen Edward Augustyn | Counter for use with a medicament dispenser |
| GB0418278D0 (en) | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Medicament dispenser |
| WO2006044133A1 (en) | 2004-09-24 | 2006-04-27 | Axys Pharmaceuticals, Inc. | Active ketone inhibitors of tryptase |
| JP5000490B2 (ja) | 2005-04-28 | 2012-08-15 | 武田薬品工業株式会社 | チエノピリミドン化合物 |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| ES2436028T3 (es) | 2006-06-23 | 2013-12-26 | Radius Health, Inc. | Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno |
| CA2698332C (en) * | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
| WO2009068652A1 (en) * | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| CA2729767A1 (en) | 2008-07-07 | 2010-01-14 | Fasgen, Inc. | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
| WO2010099054A2 (en) * | 2009-02-26 | 2010-09-02 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US20140256767A1 (en) | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| WO2013122028A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
| WO2013155528A2 (en) | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
| WO2014145642A2 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Nrf2 small molecule inhibitors for cancer therapy |
| CN105829305B (zh) | 2013-12-18 | 2018-11-30 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2调节剂 |
| TW201625601A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625586A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| KR20180018684A (ko) | 2015-06-15 | 2018-02-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| AU2016280235A1 (en) | 2015-06-15 | 2017-12-14 | Astex Therapeutics Limited | Nrf2 regulators |
| EP3307739B1 (en) | 2015-06-15 | 2020-10-07 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| EP3371167A1 (en) | 2015-10-06 | 2018-09-12 | GlaxoSmithKline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
-
2016
- 2016-10-06 US US15/765,354 patent/US10364256B2/en not_active Expired - Fee Related
- 2016-10-06 WO PCT/IB2016/055996 patent/WO2017060854A1/en not_active Ceased
- 2016-10-06 EP EP16784966.0A patent/EP3359532A1/en not_active Withdrawn
- 2016-10-06 JP JP2018517532A patent/JP2018529745A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529745A5 (enExample) | ||
| JP2019521984A5 (enExample) | ||
| KR102675041B1 (ko) | Nrf2 조절제 | |
| ES2910938T3 (es) | Reguladores de NRF2 | |
| JP2016534146A5 (enExample) | ||
| JP2006524660A5 (enExample) | ||
| JP2016514719A5 (enExample) | ||
| CN110582489A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| CN106103426B (zh) | 8-(哌嗪-1-基)-1,2,3,4-四氢-异喹啉衍生物 | |
| JP2009532452A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| WO2015092713A1 (en) | Nrf2 regulators | |
| JP2017529389A5 (enExample) | ||
| JP2016515096A5 (enExample) | ||
| JP2016505010A5 (enExample) | ||
| JP2006517591A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| HUE029366T2 (en) | Bicyclic-substituted uracil derivatives and their use | |
| JP2017500334A5 (enExample) | ||
| TWI815887B (zh) | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 | |
| JP2018529744A5 (enExample) |